Conversation With Anthony Everhart And Tim Meyer: Increasing The Usefulness Of PROs In Oncology Research

Dr. Anthony Everhart, Clinical Vice President for Internal Medicine at Signant Health, recently had the opportunity to meet with Professor Tim Meyer, who holds the position of Professor of Experimental Cancer Medicine at University College London and is also a member of the Signant Health Scientific Advisory Board.

Dr. Everhart is board-certified in internal medicine and a fellow of the American College of Physicians with over 25 years of experience in the practice of medicine and over 15 years of experience in clinical development. He regularly contributes to thought leadership through publications, webinars, and panel discussions. He currently serves as Signant’s representative on the Decentralized Trials & Research Alliance (DTRA) Leadership Council.

Tim Meyer, MD PhD, is the Cancer Director of the NIHR Wellcome UCH Clinical Research Facility and the Joint Director of the UCL ECMC. Nationally, he chairs the TRANSNET Committee, is a member of the UKNETS Steering Committee, and sits on both the Hepatobiliary and NET NIHR Clinical Studies Sub-Groups.

During their discussion, they explored present and prospective avenues for enhancing the relevance of patient-reported outcome measures in oncology research.